Behring Institute Mitteilungen最新文献

Inhalation and deposition within the the airways are the initial steps before pathogens of the respiratory tract are able to adhere and colonize their host. Once the microorganisms are deposited in the lung lining fluids they do not remain at the location where they first came in contact with the mucous membranes. It is long known that lung clearance mechanisms translocate all deposited particles. At least, most of them are swallowed and cleared via the gastrointestinal tract. Aerosol vaccination with inactivated or (recombinant) live bacteria has been shown to be an efficient way to induce local protection against lung diseases. It can be assumed that the local concentration of the vaccine and the deposition pattern of the vaccine within the lung limit the strength of a local or systemic immune response. The local concentration of airborne bacterial antigen necessary to initiate a mucosal immunity in the respiratory tract is known for a very few microorganisms. Bacterial survival, infectivity, deposition, and persistence characteristics have to be defined when aerosols are included in vaccination experiments.

This paper describes the use of human rhinovirus to display peptides corresponding to biologically active sequences. While this system can be used to reconstruct essentially any biologically active sequence for which there is a corresponding ligand that can be used for its selection, we have focused on using this system to display immunogens from dangerous pathogens as a means to develop vaccines. Five mutagenesis approaches are illustrated as ways to generate functionally active moieties. The mutagenesis approaches illustrated can be employed with any of a large number of possible display vectors; however, human rhinovirus might be especially useful in cases where it will be important to derive the benefits of delivery by a live-virus approach. Examples are shown in which reconstruction of immunogens corresponding to the V3 loop of the gp120 glycoprotein of the human immunodeficiency virus type 1 (HIV-1) on the surface of rhinovirus has yielded apparently effective mimics of the HIV-1 immunogens (as measured by their ability to be neutralized by anti-HIV-1 antibodies as well as their ability to elicit the production of antibodies capable of neutralizing HIV-1 in cell culture). This system offers the opportunity to reconstruct functionally important moieties that derive from proteins or pathogens that are either too dangerous or difficult to isolate for use as vaccine preparations themselves.

Pseudomonas aeruginosa is a common respiratory tract pathogen in certain groups of compromised hosts, most notably those with cystic fibrosis. The pathogenicity of P. aeruginosa may depend in part upon its capacity to resist normal phagocytic cell clearance. We have recently shown that phagocytosis of P. aeruginosa by macrophages is a unique two-step process; binding is glucose-independent but ingestion occurs only in the presence of D-glucose or D-mannose. P. aeruginosa is the only particle we have found which is ingested by macrophages in a glucose-dependent manner. Since glucose is present in only negligible quantities in the endobronchial space, P. aeruginosa may be pathogenic by virtue of its capacity to exploit the opportunity presented in the lower airway to resist normal nonspecific phagocytic defences. The purpose of the studies reported here is to better understand the glucose-dependent phagocytosis of P. aeruginosa and to design novel therapies to facilitate phagocytic cell clearance of it from the lower respiratory tract. We have shown that phagocytosis of unopsonized P. aeruginosa depends upon facilitated transport of glucose into macrophages via the GLUT1 isoform. After transport into the macrophage, the glucose must be metabolized to trigger phagocytosis of P. aeruginosa; pretreatment with 2-deoxyglucose or 5-thioglucose abrogates glucose-dependent ingestion. We have recently demonstrated that pulmonary alveolar macrophages (as opposed to all other macrophage phenotypes studied) lack the capacity to transport glucose and to phagocytose unopsonized P. aeruginosa; however, after the cells have been cultured in vitro for 48 hours, they are able to perform both functions. Whereas most macrophages (such as peritoneal cells) primarily depend upon glycolysis for metabolic energy, pulmonary alveolar macrophages reside in a high oxygen tension environment and appear to utilize oxidative phosphorylation. Treatment of freshly explanted pulmonary alveolar macrophages with sodium azide (to poison oxidative respiration) dramatically enhances both glucose transport and glucose-dependent phagocytosis of P. aeruginosa. We are currently investigating the compromised phagocytic function of pulmonary alveolar macrophages and the mechanism by which azide enhances glucose transport and phagocytosis of P. aeruginosa. Although physiological measurements have indicated that glucose is removed from the endobronchial space by an active transport process of the lung epithelium, the types of glucose transporters that are expressed in the lung are as yet unknown. Using RT-PCR, we have amplified a product from human and murine lung RNA which has a high degree of homology with members of the sodium-dependent glucose transporter (SGLT) family. The ultimate goal of these studies is to design novel agents for enhancing the phagocytic function of pulmonary alveolar macrophages. Delivery of simple glucose by aerosol would not be effective because (i) it would be

Using an in vitro model system we have studied parameters of both bacteria and antigen presenting cells that influence peptide presentation by murine major histocompatibility complex class II (MHC-II) and class I (MHC-I) molecules. To study MHC-II presentation, the HEL (52-61) epitope, which binds the murine MHC-II molecule I-Ak, was expressed as the cytoplasmic Crl-HEL fusion protein in S. typhimurium. When murine peritoneal macrophages mediated phagocytic processing of S. typhimurium expressing Crl-HEL, HEL (52-61) was processed and presented on I-Ak more efficiently from heat-killed S. typhimurium than from viable bacteria, and from a rough LPS strain compared to its isogenic smooth LPS counterpart, most likely due to enhanced phagocytosis of the rough LPS strain. Macrophages also processed phoP S. typhimurium strains with greater efficiency for peptide presentation by I-Ak than wild type bacteria while Salmonella constitutively expressing phoP were processed for peptide presentation by I-Ak less efficiently than wild type Salmonella. We have also shown that macrophage phagocytosis of E. coli or S. typhimurium results in presentation of bacterial antigens by MHC-I molecules. To investigate the role of post-Golgi MHC-I molecules in this presentation pathway, peritoneal macrophages from TAP1-/- mice, which are deficient in presenting endogenous antigens on MHC-I and lack significant surface MHC-I expression, were co-incubated with bacteria containing the 257-264 epitope from ovalbumin [OVA(257-264)], which binds the murine class I molecule Kb. Peritoneal macrophages from TAP1-/-/ mice could process bacteria expressing the OVA epitope for recognition by epitope-specific T hybridoma cells. This processing and presentation was reduced in efficiency between three to 100 fold compared to C57BL/6 macrophages, depending on the protein harbouring the OVA (257-264) epitope (Crl-OVA or native OVA). This suggests that the protein context of the OVA (257-264) epitope influences the extent of TAP-independent processing for MHC-I presentation. In addition, we show that murine bone marrow-derived dendritic cells can phagocytose and process viable gram negative bacteria for peptide presentation on MHC-I and MHC-II; inhibition studies showed that acidic compartments in dendritic cells are required for this presentation. These results suggest that dendritic cells may be potential antigen presenting cells used in eliciting specific immune responses against bacteria.

Insertion of additional epitopes to outer membrane proteins can lead to display of the hybrid protein on the bacterial outer surface. OmpS is the maltoporin of Vibrio cholerae and forms trimeric pores which function in uptake of maltose and maltodextrins through the membrane. OmpS is present in all V. cholerae 01 and 0139 strains. Each monomer traverses the membrane 18 times and has thus 9 loops facing the outside world. We have developed an ompS-expression-plasmid based system where foreign epitopes can be inserted in one of its surface accessible loops leading to production of a hybrid protein which still has the normal OmpS folding and function. The immunogenic peptides tested as OmpS hybrids include the CTP3 epitope of cholera toxin B-subunit and the C3 epitope of poliovirus. These hybrids can be detected with epitope-specific antisera on the bacterial cell surface. OmpS hybrid proteins carrying 38, 76 or 115 aa of the fibronectin binding D1-D3 repeats of FnBPA of Staphylococcus aureus have been tested for binding characteristics.

Proinflammatory cytokines such as tumor necrosis factor alpha (TNF alpha) are important immunoregulatory mediators of the antibacterial host defense. Previous studies have suggested that virulence of pathogenic Yersiniae is associated with suppression of the local cytokine response. In this context, the plasmid-encoded 41 kDa Yersinia outer protein B (YopB) has been implicated with a lack of TNF alpha expression in Peyer's Patches (PP), following oral infection of mice with the enteropathogenic Yersinia enterocolitica. The present study was performed to further evaluate the relationships between YopB-induced suppression of TNF alpha and bacterial survival in host tissue. Results are presented to show the ability of purified YopB to suppress the release of TNF alpha by macrophages. In mice orally infected with Y. enterocolitica, anti-YopB treatment on days 3 and 5 postinfection, significantly decreased the recovery of live bacteria from PP. This observation correlated with a strong increase in TNF alpha expression, as determined by RT-PCR and measuring the levels of TNF activity in homogenates of PP. Moreover, treatment of mice with a combination of anti YopB and anti-TNF alpha antiserum, completely abrogated the beneficial effect of the anti-YopB antiserum. In controls, expression of other proinflammatory cytokines such as IL-1 remained unaffected by either treatment. Therefore, the results indicate that endogenous TNF alpha is required for eradication of Y. enterocolitica from host tissue and further imply that YopB significantly contributes to suppression of the local TNF alpha response in PP.